Proteomics helps to understand the basic biological processes critical to normal cellular functions as well as the development of diseases. It identifies the essential components of these processes and exploits these components as targets in the development of new methods to prevent or treat diseases. Proteomics, although in an infancy stage in India, has the potential to complement and further enlarge the wealth of information in medicine, especially in the field of cancer. This article reviews the recent progress in proteomic techniques and their applications in the field of obstetrics and gynecology.
markers for use in the screening, early diagnosis and prediction of response to therapy. [1] Mass spectrometers (MSs) like matrix-assisted laser at the bedside for discovering protein patterns that distinguish disease from disease-free states with a high sensitivity and specificity. [2] 
Proteomics in Gynecology
Cervical cancer is one of the leading causes of cancer morbidity and mortality in women worldwide. More than 98% of the cases are related to a Human papilloma virus (HPV) infection. Researchers are working on the identification and functional verification of host proteins associated with HPV E6 and E7 oncoproteins. This may provide useful information for understanding cervical carcinogenesis and development of cancer-specific markers. In addition, proteomic profiling of altered proteins by anticancer drugs on cervical cancer may contribute to providing the fundamental resources for investigation of disease-specific target proteins, elucidation of novel mechanisms of action and development of new drugs. [3] 
Introduction
The Human Genome Project had made the scientific community and public believe that all biology and medicine would become understandable after the sequencing of the DNA. As biology is much more complicated than the structure and function of nucleic acids, the practical applications are quite limited. The study of living systems has now expanded past genomics based on the rationale that it is the protein products of the gene and not simply gene expression that have effects and cause disturbances at the cellular level. Its advent has provided the hope of discovering novel biological techniques are now being employed to identify proteins that are potential biomarkers of the disease. [4] The urgent need of biomarkers accurately detecting early-stage epithelial ovarian cancer has prompted many research groups to enter in a search for specific peptide signatures that may discriminate transformed cells from those of the normal ovarian microenvironment.
CA-125, the most widely used biomarker for ovarian cancer, does not have a high positive predictive value, and it is only effective when used in combination with other diagnostic tests [ Table 1 ].
[5] A combination of mass spectra generated by new proteomic techniques such as SELDI-TOF-and artificial intelligence-based informatic algorithms have been used to discover a small set of key proteins in order to discriminate between normal and patients with ovarian cancer. Serum protein pattern analysis might be applied ultimately in medical screening clinics as a supplement to thediagnostic work up and evaluation. [6] [7] [8] [9] 
Proteomics in Obstetrics
Pre-eclampsia is a pregnancy-specific syndrome and a major cause of maternal mortality. X-ray of the gastrointestinal tract Ultrasound (pelvic and/or transvaginal): It can help determine whether an ovarian growth is likely to be a cancer or a fluid-filled cyst.
CT scan (pelvis) pregnant women, followed by comparison of the profiles. Clusterin was identified by MALDI-TOF-MS followed by peptide mass fingerprinting, a protein database search and Western blot analysis. [16] Mine and colleagues found dynactin, a protein related to cell turnover in placental proteome maps, by novel 2D-immunoblotting analysis. [17] Myers et al. carried out a pilot study to use protein chip technology to determine differences in protein profiles in plasma taken at 26 weeks from women at risk of developing pre-eclampsia. They found five proteins upregulated significantly in samples from women who subsequently developed pre-eclampsia compared with women who remained normotensive. [18] Recent evidence suggests that a major cause of prematurity-associated (MR score). MR score presents a gradient of disease activity progressing from "absent," "mild" to "severe" inflammation. Thus, it provides the ability to identify patients who might benefit from interventions in utero in a modern diagnostic-therapeutic framework. [19] Others Proteomic tools are being applied in varied fields related with reproductive function, such as the study of oocyte maturation, spermatogenesis and fertilization in mammals. [20] [21] [22] [23] The identification of specific genes in oocytes and embryos is now possible with the use of powerful tools such as library analysis or subtractions, DNA array, comparative analysis of databanks from other mammals and 2D-gel electrophoresis analysis. Finally, RNA interference is a useful tool for studying gene function by knocking out the activity of specific genes, and will be used in oocytes and embryos. [24] Amniotic fluid is a potential source of biomarkers for many disorders that may occur during pregnancy or for embryonic abnormalities.
Proteomics have already been applied in the analysis of tissues from fetuses with Down's syndrome. [25] The 
Conclusion
Looking back, it seems that the major outcome of human genome sequencing has finally been to open the way to exploration of the proteome. Perhaps the most promising outcome of the work reported by scientists is the interface between proteomic technology and bioinformatics. The rapid explosion in the amount of data being generated by current genomic and proteomic technology already exceeds the analytical capacity of the human mind. The need for increasing sophistication in data management and statistical interpretation and attention to this aspect of research is critical to its successful translation into clinical practice. [27] 
